Amgen, Servier advance cardiovascular collaboration
Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure. Read More »
 
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
                 
                 
                 
                 
                 Alerts Sign-up
          Alerts Sign-up